Latest Articles

Publication Date
Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.

Uterine fibroids and endometriosis are among the most common conditions encountered in gynaecological practice. Fibroids affect 30-70% of women, with up to half experiencing symptoms that significantly impair quality of …

Published: July 28, 2025, midnight
Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial.

Is oral administration of a gonadotrophin releasing hormone (GnRH) antagonist for 2 months before euploid embryo transfer in patients with endometriosis non-inferior to intramuscular administration of a long-acting GnRH agonist …

Published: July 11, 2025, midnight
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.

Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …

Published: April 3, 2025, midnight
Fertility preservation in women with endometriosis: A retrospective non-Inferiority study comparing Dienogest in the PPOS protocol to antagonist and agonist protocols.

Endometriosis is a common pathology that can lead to a decrease in fertility and is therefore a medical indication for preserving fertility. Traditionally, gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols …

Published: April 3, 2025, midnight
Dydrogesterone is an eligible tool to suppress LH surge in assisted reproduction technologies (ART) cycles.

To evaluate Dydrogesterone's effectiveness in PPOS protocols for IVF/ICSI or oocyte cryopreservation, focusing on LH surge suppression and metaphase II oocyte yield.

Published: March 13, 2025, midnight
The Molecular and Cellular Mechanisms of Endometriosis: From Basic Pathophysiology to Clinical Implications.

Endometriosis is a complex gynecological disorder characterized by endometrial-like tissue growing outside the uterus, leading to chronic pain, infertility, and reduced quality of life. Its pathophysiology involves genetic, epigenetic, immune, …

Published: March 10, 2025, midnight
Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …

Published: Feb. 6, 2025, midnight
The effect of dienogest and gonadotropin-releasing hormone agonist on pelvic pain after laparoscopic surgery for endometriosis: An RCT.

Endometriosis is a chronic inflammatory condition associated with debilitating chronic pelvic pain that affects women's quality of life. Several drugs have been used to reduce pain and psychological distress associated …

Published: Jan. 31, 2025, midnight
Weighing up GnRH agonist therapy for endometriosis: outcomes and the treatment paradigm.

Endometriosis is a chronic inflammatory estrogen-dependent disease affecting 10% of women worldwide leading to chronic pelvic pain and infertility which may be treated clinically or surgically.

Published: Jan. 25, 2025, midnight
Hormone receptor profile of ectopic and eutopic endometrium in adenomyosis: a systematic review.

What is the hormone receptor profile of adenomyosis lesions in comparison to correctly located endometrium?

Published: Jan. 20, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!